Comparative pharmacology of a new recombinant FSH expressed by a human cell line by Koechling, Wolfgang et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Comparative pharmacology of a new recombinant FSH expressed by a human cell line
Koechling, Wolfgang; Plaksin, Daniel; Croston, Glenn E.; Jeppesen, Janni V.; Macklon,
Kirsten T.; Andersen, Claus Yding
Published in:
Endocrine Connections
DOI:
10.1530/EC-17-0067
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Koechling, W., Plaksin, D., Croston, G. E., Jeppesen, J. V., Macklon, K. T., & Andersen, C. Y. (2017).
Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocrine Connections,
6(5), 297-305. https://doi.org/10.1530/EC-17-0067
Download date: 03. Feb. 2020
This work is licensed under a Creative Commons 
Attribution 4.0 International License.DOI: 10.1530/EC-17-0067
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
6
3
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:3 297–305W Koechling, D Plaksin et al. Comparative pharmacology of follitropin delta
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
Open Access
Comparative pharmacology of a 
new recombinant FSH expressed by 
a human cell line
Wolfgang Koechling1,*, Daniel Plaksin2,*, Glenn E Croston3, Janni V Jeppesen4, 
Kirsten T Macklon4 and Claus Yding Andersen4
1Ferring Pharmaceuticals A/S, Copenhagen, Denmark
2Bio-Technology General Israel Ltd, Ferring Pharmaceuticals, Kiryat Malachi, Israel
3Croston Consulting, San Diego, California, USA
4The Laboratory of Reproductive Biology, The Department of Fertility at The Juliane Marie Centre, 
Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark
*(W Koechling and D Plaksin contributed equally to this work)
Abstract
Recombinant FSH proteins are important therapeutic agents for the treatment of 
infertility, including follitropin alfa expressed in Chinese Hamster Ovary (CHO) cells 
and, more recently, follitropin delta expressed in the human cell line PER.C6. These 
recombinant FSH proteins have distinct glycosylation, and have distinct pharmacokinetic 
and pharmacodynamic profiles in women. Comparative experiments demonstrated that 
follitropin delta and follitropin alfa displayed the same in vitro potency at the human 
FSH receptor, but varied in their pharmacokinetics in mouse and rat. While follitropin 
delta clearance from serum depended in part on the hepatic asialoglycoprotein receptor 
(ASGPR), follitropin alfa clearance was unaffected by ASGPR inhibition in rat or genetic 
ablation in mice. The distinct properties of follitropin delta and follitropin alfa are likely 
to contribute to the differing pharmacokinetic and pharmacodynamic profiles observed 
in women and to influence their efficacy in therapeutic protocols for the treatment 
of infertility.
Introduction
Follicle-stimulating hormone (FSH) released from the 
anterior pituitary in response to gonadotropin-releasing 
hormone (GnRH) plays a central role in reproduction in 
women, driving the growth and maturation of ovarian 
follicles, and regulating ovarian steroidogenesis (1). 
In addition, exogenous FSH plays a central role in the 
treatment of infertility (2), including in vitro fertilization 
(IVF) or intracytoplasmic sperm injection (ICSI), with 
the GnRH antagonist protocol increasingly common 
due to safety and convenience (3). As a result, continued 
innovation in infertility therapy is likely to involve both 
novel FSH proteins and novel treatment protocols.
FSH is composed of two extensively glycosylated 
protein subunits, and to express recombinant FSH (rFSH) 
for therapeutic use, the genes encoding the human FSH 
subunits are introduced into a mammalian cell line from 
which FSH protein is secreted and purified (4). Early 
recombinant FSH proteins expressed in Chinese Hamster 
Ovary (CHO) cells are termed follitropin alfa or follitropin 
beta (4, 5, 6), and display distinct glycosylation compared 
to urinary-derived endogenous human FSH, occurring as 
a range of isoforms of varying acidity that are on average 
slightly less acidic in isoelectric focusing (7). Compared to 
human urinary FSH, CHO cell-derived rFSH lacks bisecting 
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GlcNAc residues, has a lower percentage of alpha 1–6 
fucose and lacks alpha 2,6-linked sialic acid, while urinary 
FSH contains both alpha 2,3- and alpha 2,6-linked sialic 
acid (7, 8, 9).
Recently follitropin delta has been described (FE 
999049), the first recombinant FSH protein in clinical 
development that is expressed in a human cell line 
(PER.C6), with individualized dosing optimized based 
on each patient’s weight and anti-Mullerian hormone 
(AMH) level (10, 11, 12). In female volunteers, 
follitropin delta displayed distinct pharmacokinetics and 
pharmacodynamics, with higher exposure and lower 
serum clearance than follitropin alfa (13). Moreover, 
the outcome of this phase 1 study demonstrated that 
the bioactivity of follitropin delta in the rat Steelman–
Pohley assay compared to a reference standard did not 
directly predict proportional pharmacodynamic activity 
in women (13). These observations suggest that improved 
understanding of the distinct pharmacodynamics and 
pharmacokinetics of these recombinant FSH proteins will 
aid in their therapeutic application.
While follitropin alfa and follitropin delta have 
the same amino acid FSH sequence, they vary in 
their glycosylation (14). Follitropin delta has a higher 
proportion of tri- and tetra-sialylated glycans, with both 
alpha2,3- and alpha2,6-linked sialic acid, while follitropin 
alfa has only alpha2,3-linked sialic acid, in addition to 
other differences in glycosylation. More acidic isoforms 
of FSH with greater sialic acid modification and a lower 
isoelectric point are less potent in vitro at the human FSH 
receptor compared to more basic FSH isoforms, and also 
display lower serum clearance and longer circulating half-
life (15, 16, 17, 18, 19).
To examine how the distinct glycosylation of 
follitropin alfa and follitropin delta affects their 
pharmacological activity, the in vitro and in vivo 
bioactivity of both recombinant FSH preparations 
was directly compared. For this purpose, the binding 
affinities of follitropin delta and follitropin alfa at 
the human FSH receptor were determined, and their 
bioactivities were tested in a HEK-293 cell line stably 
expressing the human FSH receptor, and in human 
granulosa cells isolated during oocyte pick-up prior to 
IVF. The pharmacokinetic behavior of the two rFSH 
proteins was also analyzed in rodents, examining the 
role of the ASGP receptor in mouse and rat on rFSH 
clearance from circulation.
Methods
Follitropin alfa and follitropin delta
Follitropin alfa produced in CHO cells was obtained from 
the market (Gonal F, Merck Serono, Batches BA018199A, 
AU009535, AU003768, BAD 04143, PS-3577, Y02A9111), 
and diluted and tested as indicated in each experimental 
method. Follitropin delta samples produced in the human 
cell line PER.C6 were provided by Ferring Pharmaceuticals 
(Batches FSMB01/2, G16641, G11105, CE0041, 1178-160) 
and characterized and diluted for testing as indicated 
in each experimental procedure. The first international 
standard for recombinant FSH (NIBSC 92/642) was 
obtained from NIBSC (National Institute for Biological 
Standards and Control).
Human FSH receptor binding
The binding displacement assay for the human FSH 
receptor was performed utilizing [Propionyl-3H] FSH as 
the radiolabel (Quotient Research, UK). Incubation Buffer 
and Stop Buffer was 10 mM Tris, 25 mM MgCl2, 0.5% BSA, 
pH 7.5. Follitropin delta used in these experiments had 
a protein concentration of 0.62 mg/mL and an assumed 
molecular weight of 33,000 g/mol. A sample of follitropin 
alfa with an assumed molecular weight of 31,000 g/mol, 
with 5.5 µg or 75 IU powder dissolved in 1.2 mL of the 
incubation buffer and the stock solution at 0.15 µM was 
aliquoted and stocked at −20°C. For both compounds, all 
dilutions were performed in the incubation buffer.
To make membranes, a frozen pellet of HEK-293 
cells expressing human FSH receptor (approximately 
600 million cells) was suspended in buffer containing 
50 mM Tris–HCl, 5 mM EDTA–Tris, 20 mM NaCl, 5 mM 
KCl, 5 mM MgCl2, 1.5 mM CaCl2, 10 μg/mL trypsin 
inhibitor, 1 μg/mL leupeptin, 75 μg/mL PMSF, pH 7.4. After 
centrifugation at 50,000 g for 15 min (4°C), the pellet was 
suspended in the same buffer with the addition of 10% 
glycerol. The protein concentration was determined with 
the Bradford methodology and the aliquots was stored 
at −80°C.
To initiate binding, FSH receptor membranes 
containing 180 µg protein were incubated one hour at 
37°C with 0.4 nM of [Propionyl-3H] FSH and the indicated 
quantity of follitropin alfa or follitropin delta. Unifilter 
GF/B filters (Whatman, UK) were pre-soaked with 10 mM 
Tris–HCl, 25 mM MgCl2, 0.5% BSA, pH 7.5. Incubated 
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mixtures were filtered through pre-soaked filters using a 
Packard FilterMate Harvester, and washed 3–4 times using 
the same buffer. Filters were then dried, MICROSCINT 0 
scintillation fluid (PerkinElmer) was added (30 µL/well) 
and scintillation counting was performed using a Packard 
Topcount NXT instrument (1 min per well).
Ki was estimated by the Cheng–Prusoff equation (20).
In vitro bioactivity using a HEK-293 cell line 
expressing the human FSH receptor
Human embryonic kidney 293 (HEK-293) cells stably 
transfected with the human FSH receptor (21) were 
thawed from frozen aliquots, and grown and passaged 
in DMEM with 4.5 g/L d-glucose (Biological Industries, 
Israel) containing 5% fetal bovine serum, heat inactivated 
(Biological Industries) and 2 mM l-glutamine (Biological 
Industries). For assays, hFSH receptor expressing cells 
were incubated with the indicated concentrations of 
rFSH proteins for 90 min. At the end of the incubation, 
cells were lysed and cAMP produced in response to rFSH 
stimulation quantitated using the DiscoveRx HitHunter 
cAMP XS + cAMP assay kit (DiscoveRx, Fremont, CA, USA), 
measuring luminescence using the TECAN Infinite F200 
plate reader and reporting RLU. Data were analyzed using 
four-parameter curve-fitting (Graphpad Prism).
In vitro bioactivity using fresh luteinized granulosa 
cells from IVF patients
To determine the activity of rFSH proteins, human 
granulosa cells were collected from 13 women ages 
26–39  years (34.5 ± 1.2  years, mean ± s.e.m.) undergoing 
IVF treatment at the University Hospital of Copenhagen, 
with approval of the project by the ethical committee 
of the municipalities of Copenhagen and Frederiksberg 
(H-32013-201). The studies in which rFSH proteins were 
compared utilized cells from eight of these patients. 
Women were either stimulated following a long agonist 
protocol or a standard antagonist protocol. In all cases, 
a bolus injection of hCG was used for final oocyte 
maturation 36 h prior to oocyte collection. Granulosa 
cells were collected in connection with aspiration of 
oocytes for IVF treatment. After oocytes were removed 
from the follicular aspirates, the granulosa cells from 
each patient were collected in a pool and purified using 
a lymphoprep gradient (Stemcell Technologies, Grenoble, 
France) where fluid was maintained in the upper layer, 
while red blood cells were collected in the pellet and the 
granulosa cells were located in the intermediate layer. 
After aspiration of the granulosa cells layer, large clumps 
of cells were removed under a microscope and stored at 
−80°C until used for DNA purification and detection of 
the 307/680 FSHR and the −29 FSHR polymorphism of the 
patient (22). A single cell suspension of granulosa cells was 
prepared from the smaller clumps of cells by the addition 
of the proteolytic enzyme mix Tryple (mainly trypsin) 
for up to 5 min or until the clumps became disintegrated. 
Proteases were inactivated by the addition of FBS, and the 
suspension was centrifuged (400 g 10 min) to pellet the 
granulosa cells. Granulosa cells were cultured in 4-well 
dishes (Nunc, Roskilde, Denmark) at 37°C with 6.5% O2 in 
culture medium consisting of MEM Alpha medium (Gibco) 
supplemented with human serum albumin 10 mg/mL 
(CSL Behring, Lyngby, Denmark); 50 mg/mL FBS (Gibco); 
2 mM GlutaMAX (Gibco), Insulin–Tranferrin–Selenium 
mix (Gibco); and Pen/strep (Gibco). The first 24 h cells 
were allowed to attach to the bottom in the presence 
of 50 mg/mL FBS after which the culture medium was 
changed. After 48 h, cells were stimulated by rFSH for 
24 h. Thereafter the media was harvested, snap frozen and 
stored at −80°C until thawed for hormone measurements. 
The cells attached to the bottom were washed in pre-
warmed PBS (Gibco) prior to being lysed. The granulosa 
cells were lysed with the lysis buffer purchased with the 
mRNA purification kit (see below), snap frozen and stored 
at −80°C until RNA purification and qPCR.
Purification of mRNA was performed using Agilent 
Absolutely RNA nanoprep kit (Agilent Technologies). All 
steps were performed on ice, apart from the elution of 
isolated mRNA. First strand cDNA synthesis was performed 
using Applied Biosystems High Capacity cDNA reverse 
transcription kit (Applied Biosystems) with following 
temperature profiles: 25°C for 10 min, 37°C for 120 min, 
85°C in 5 s and 4°C until the synthesis was terminated. 
All first-strand cDNA syntheses were performed on a 
Thermal cycler (ThermoFisher Scientific Arktik thermal 
cycler block). TaqMan Universal PCR master mix (Applied 
Biosystems) and pre-designed TaqMan probes were tagged 
with a FAM-labeling (Applied Biosystems): Cyp19a1 
(Hs00903412_m1), 3beta-HSD (Hs01084547_gH), INHA 
(HS00171410_m1) and GAPDH (Hs99999905_m1) as a 
housekeeping gene. qPCR reactions were performed in a 
total volume of 10 µL consisting of a mixture of 0.5 µL 
20× TaqMan gene expression assay, 5.0 µL 2× TaqMan 
gene expression master mix, 2.0 µL cDNA and 2.5 µL 
RNase free water for each single reaction. The qPCR plates 
(Roche Diagnostics) were centrifuged at 1000 g before 
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analysis using the LightCycler 480 (Roche) with the 
following program for 45 cycles; pre-incubation: 50°C for 
2 min, followed by 95°C for 10 min, amplification at 95°C 
for 15 s and 60°C for 1 min, followed by a quantification 
measurement, ending by cooling to 40°C in 30 s. All 
samples were run in duplicates and normalized to the 
corresponding GAPDH gene expression value.
The calculation of the expression level of each 
individual gene was carried out according to the 
Comparative CT Method for relative quantification of 
gene expression (23). Concentrations of estradiol and 
progesterone were measured using commercially available 
ELISA kits (NovaTec Immundiagnostica, Germany). A PBS 
solution containing 1% BSA was used for dilution of the 
culture media samples prior to measurements. Dilutions 
of 1:10 for estradiol and 1:500 of progesterone secured 
readings inside of the standard curve. All samples were 
run in duplicate, and the mean of the replicates was 
used. Inhibin A and inhibin B were measured using 
commercially available ELISA kits (AnshLabs, Webster, 
USA). Serum from post-menopausal women devoid of 
inhibin A and inhibin B was used to dilute samples.
Steelman–Pohley assay
Follitropin alfa was obtained from a freeze-dried vial stated 
by the manufacturer to contain 600 IU of rFSH per and 
filled by mass to contain 44 µg of FSH per mL. Follitropin 
delta was measured by size exclusion chromatography 
HPLC to contain 39 µg of FSH per mL and 600 IU/mL in 
liquid formulation.
The Steelman–Pohley assay (24) was performed 
according to USP monograph for Menotropins and the 
Ph Eur monograph for Urofollitropin (USP Monograph: 
Mentotropins 4/30/08, PhEUR: Urofollitropin 
01/2008/0958), with immature female Sprague–Dawley 
rats (Harlan, Jerusalem, Israel), 20–21 days old (35–45 g) 
having weights such that the difference between the 
heaviest and the lightest rat is not more than 10 g. Animals 
were fed a standard diet and allowed free access to water, 
randomly distributing animals for the experiment with 
seven animals in each group.
Solution A used for the dilution of proteins for 
injection was 130 mM NaCl, 75 mM Na2HPO4–2H2O, 0.1% 
BSA, pH 7.5. hCG was diluted to 700 IU/mL in Solution B, 
which includes 130 mM NaCl, 75 mM Na2HPO4–2H2O, 1% 
BSA, pH 7.5, and further diluted in Solution A to 70 IU/mL, 
which was then used for the preparation of proteins and 
controls for injection.
For each rFSH protein, a 0.2 mL volume was 
injected once per day for three days at three dose levels 
subcutaneously in the dorsal area for each, according 
to established assay guidelines, with the injection also 
containing 14 IU of hCG (Serono). The weight of each 
animal was recorded at the beginning and end of each 
experiment. Twenty-four hours after the last injection, 
animals were killed, and ovaries were removed and 
cleaned of extraneous tissues, blotted dry, and pairs of 
ovaries weighed.
Specialized rat pharmacokinetics (ASF competition)
Identical volumes (0.5 mL) and concentrations (4 µg/mL) 
of follitropin delta and follitropin alfa were injected IV 
into male Sprague–Dawley rats weighing 80–85 g (Harlan) 
in the presence and absence of asialofetuin (Sigma). 
Animals (2 per treatment group) were bled at specific 
time points (0.25, 1, 2 and 4 h post injection), and sera 
were tested for FSH concentration by ELISA in duplicates 
(DRG Instruments GmbH, Marburg, Germany). For the 
ELISA, 100 µL of anti-FSH enzyme conjugate was added 
to samples, and plates were incubated for 30 min at room 
temperature. Contents of wells were removed and rinsed 5 
times with water, inverting plates to dry. Substrate solution 
was added and incubated 5 min at room temperature 
before adding 50 µL of stop solution, and absorbance was 
read at 450 nM. The anti-human FSH antibody used in 
the ELISA for the detection of recombinant human FSH 
proteins displayed no measureable interference from rat 
or mouse serum (data not shown). Results in the presence 
and absence of ASF were compared using a Student’s t-test 
at P < 0.05.
Specialized mouse pharmacokinetics  
(Asgpr knockout model)
Homozygous asialoglycoprotein receptor knockout (KO) 
mice (B6;129S7-Asgr2tm1Her/J) (25) were obtained from 
The Jackson Laboratory, and wild-type C57Bl/6J mice were 
obtained from Harlan Laboratories. Weight of the mice 
was from 22 to 24 g. Follitropin alfa freeze-dried powder 
was reconstituted in the laboratory with dissolving 
solution supplied. Follitropin delta drug product was 
received in a solution form. Identical volumes (0.5 mL) 
and concentrations (6 µg/mL) of follitropin alfa and 
follitropin delta were injected subcutaneously (SC) into 
both male C57Bl/6J mice and male Asgpr knockout mice. 
Animals (n = 3 per treatment group) were bled at specific 
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time points thereafter (0.5, 3, 6, 9 and 24 h post dosing), 
and sera were tested for FSH concentration by ELISA in 
triplicates.
The mean serum concentrations of follitropin delta 
were normalized based on the ELISA concentration of the 
original injected vials compared to follitropin alfa. Serum 
FSH concentration vs time was plotted, and a classical 
trapezoidal rule was used to compute the area under the 
curve (AUC) by ‘PK Solutions 2.0’ software. The AUC 
value of FE follitropin delta is presented as a percent of the 
AUC value calculated for follitropin alfa. Results at each 
time point were compared between wild-type and Asgpr 
knockout animals using a Student’s t-test with P < 0.05 as 
the criteria for significance.
Results
Human FSH receptor binding
FSH receptor binding affinity was measured by 
displacement of radiolabeled FSH from the human 
FSH receptor. Propionyl-3H labeled FSH was used as the 
radiolabeled ligand in these studies, with membranes 
prepared from recombinant HEK 293 cells expressing 
the human FSH receptor. The Kd value of [Propionyl-
3H] 
FSH in this assay was 0.2 nM with a Bmax of 28 fmol/
mg protein (data not shown). The average IC50 in three 
experiments for displacement of propionyl-3H FSH was 
virtually identical for the two rFSH proteins, 0.302 nM for 
follitropin alfa and 0.299 nM for follitropin delta, with the 
results from a representative experiment shown in Fig. 1, 
resulting in a calculated Ki of approximately 0.1 nM for 
both proteins.
In vitro bioactivity using a HEK-293 cell line 
expressing the human FSH receptor
To compare the in vitro bioactivity of follitropin delta and 
follitropin alfa, both rFSH proteins were incubated in vitro 
with human embryonic kidney cells (HEK-293 cells) 
engineered to stably express the human FSH receptor, 
measuring production of the second messenger cAMP. The 
potency of the two rFSH proteins was virtually identical in 
this assay (Fig. 2), with follitropin alfa activating the hFSH 
receptor with an EC50 of 0.0174 nM, and follitropin delta 
producing an EC50 of 0.0171 nM. In a second independent 
experiment, follitropin alfa produced an EC50 of 0.0182 nM 
and follitropin delta produced an EC50 of 0.0181 nM (data 
not shown).
In vitro bioactivity using fresh luteinized granulosa 
cells from IVF patients
The in vitro bioactivity of follitropin delta and follitropin 
alfa was then compared using luteinized granulosa cells 
isolated from follicles of IVF patients and expressing the 
endogenous human FSH receptor. These experiments 
examined the impact of rFSH proteins on granulosa cell 
production of estradiol, progesterone, inhibin A and 
Figure 1
The displacement of radiolabeled propionyl-3H FSH from human FSH 
receptor was measured as a reduction in dpm bound across the indicated 
concentrations of follitropin delta (open circles, blue) and follitropin alfa 
(open squares, red), or total binding in the absence of unlabeled 
recombinant FSH protein (open triangle, black). Each concentration was 
tested in duplicate, with the mean and s.d. indicated. Data were fit using 
four-parameter curve-fitting. The results for one experiment are shown, 
whereas results from two other tests producing similar results are 
not shown.
Figure 2
Production of cAMP in response to activation of the human FSH receptor 
in stably transfected HEK-293 cells was measured across the indicated 
concentrations of follitropin delta (open circles, blue), follitropin alfa 
(open squares, red) or no recombinant FSH (open triangles, black) with 
increasing luminescence (RLU) proportional to increasing cAMP present. 
Each concentration of rFSH proteins was tested in quadruplicate, with the 
mean and s.d. shown.
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inhibin B, and on the expression of genes including 
CYP19a1, 3B-HSD and Inh A. Granulosa cells were 
collected following triggering of final follicle maturation 
at oocyte pickup from a total of 13 women undergoing 
controlled ovarian stimulation prior to IVF. Both rFSH 
proteins induced progesterone production approximately 
300% normalized to basal levels in the absence of rFSH 
(P > 0.1), and with similar potency (Fig.  3A). Inhibin 
A in supernatant was increased by both rFSH proteins 
approximately 35–40% over basal (Fig. 3B), while estrogen 
and inhibin B were not significantly increased by either 
rFSH protein (data not shown). The expression of FSH 
regulated genes was studied in the same human granulosa 
cell studies, preparing RNA at the end of the incubation 
period to be quantitated. Expression of 3B-HSD was 
induced approximately 200% by both rFSH proteins 
(Fig. 3C), the CYP19a1 gene was induced 40–50% by both 
rFSH proteins (data not shown) and INHA expression was 
induced by both rFSH proteins 50–100% over basal levels 
(data not shown).
Steelman–Pohley assay
The Steelman–Pohley bioassay concept was used to 
demonstrate the bioactivity of follitropin delta in rat 
compared to an international reference standard of 
recombinant FSH produced in CHO cells. When follitropin 
delta and follitropin alfa were compared by Steelman–
Pohley assay based on dosing of a previously assessed 
bioactivity, the two compounds produce parallel curves 
and, thus, are very similar in their pharmacodynamic 
behavior in rat (Fig. 4).
Specialized rat pharmacokinetics (ASF competition)
To examine the role of the ASPGR in clearance of 
follitropin delta and follitropin alfa, the rFSH proteins were 
injected intravenously in rats in the presence or absence 
of a saturating dose of asialofetuin (ASF), a ligand for the 
ASGPR that can compete and block the hepatic clearance 
of other ASGPR ligands. Co-injection of a saturating dose 
of ASF reduced the clearance of follitropin delta from 
serum, resulting in a 42% increase in the AUC compared 
to the absence of ASF (Fig. 5) and a significant difference 
in ASF level in plasma at one hour while co-injection with 
ASF did not significantly affect follitropin alfa clearance 
or plasma levels.
Figure 3
The induction of hormone release and increase in gene expression were 
measured in human granulosa cells exposed to rFSH proteins in vitro. 
Cells from eight patients were included, with duplicate samples of cells 
from each patient tested at each rFSH concentration, normalizing 
responses relative to the level observed in the absence of rFSH (100%), 
with data points reflecting the mean and s.e.m. The response for 
follitropin delta (open circles, blue) and follitropin alfa (open squares, 
red) is shown in terms of progesterone secretion (A), inhibin A secretion 
(B) and 3beta-HSD gene expression (C).
Figure 4
The bioactivity of follitropin delta (blue bars) and follitropin alfa  
(red bars) was compared in vivo in rat in the Steelman–Pohley bioassay, 
measuring the increase in ovarian weight with the administration of the 
indicated total dose of rFSH proteins. Bars are the mean of 14 animals in 
each dose group, and error bars are the s.d.
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Specialized mouse pharmacokinetics  
(Asgpr knockout model)
To further examine the role of ASGPR in clearance of 
follitropin alfa and follitropin delta, their pharmacokinetics 
were compared in wild-type and ASGPR knockout mice, 
injecting identical volumes and concentrations of protein 
subcutaneously (Fig.  6). Follitropin alfa and follitropin 
delta displayed similar pharmacokinetic profiles following 
subcutaneous injection in wild-type mice. In ASGPR 
deficient mice, however, follitropin delta clearance from 
serum was reduced, and the AUC in serum following 
follitropin delta injection increased 40% compared to 
follitropin alfa, with a significant difference in plasma 
concentrations at the six- and nine-hour time points, 
further supporting the hypothesis that follitropin delta 
clearance from serum involves the ASGPR while follitropin 
alfa clearance relies less on this mechanism.
Discussion
Follitropin delta and follitropin alfa display distinct 
pharmacokinetic and pharmacodynamic properties in 
healthy female volunteers, with follitropin delta displaying 
lower clearance from serum, producing greater exposure 
and a greater pharmacodynamic response (13). In addition, 
follitropin delta displays a noninferior pregnancy rate and 
live birth rate compared to follitropin alfa, with a reduced 
rate of complications such as OHSS (39). The differences 
observed clinically between the two rFSH proteins might 
be caused by differences in their glycosylation (14) since 
variations in glycosylation have been reported to affect 
FSH pharmacokinetics and pharmacodynamics (15, 16, 
17, 18, 19). To better understand the clinical differences 
observed between the two rFSH proteins, we compared 
their signaling through the human FSH receptor and their 
pharmacokinetics in rodents.
When compared directly it was found that follitropin 
delta and follitropin alfa elicit indistinguishable activity 
at the human FSH receptor in vitro. The two rFSH proteins 
displayed the same apparent binding affinity for the 
human FSH receptor, and virtually identical potency 
in the activation of the human FSH receptor in a HEK-
293 cell-based assay, measuring the induction of cAMP 
production in response to agonist ligand. Differences in 
the clinical activity of the two rFSH proteins are unlikely 
to be caused by differences in their binding and activation 
of the FSH receptor.
Further comparing the two rFSH proteins, they 
produced similar in vitro responses in patient-derived 
luteinized granulosa cells, measuring FSH-induced 
hormone production and gene regulation. In addition 
to inducing progesterone production to similar levels, 
both rFSH proteins increased 3B-HSD expression, the 
enzyme responsible for the conversion of pregnenolone 
to progesterone (26). The modest induction of CYP19a1 
gene expression by both rFSH proteins is consistent with 
previous reports in granulosa cells (27, 28, 29) as was the 
induction of both INHA gene expression and inhibin A 
protein secretion (30). The lack of increase in estrogen 
and inhibin B in these studies is consistent with the 
stage at which the granulosa cells were collected, after 
patients had been through controlled ovarian stimulation 
and triggering of final oocyte maturation, shifting them 
from follicular gene expression and hormone production 
toward luteal phase gene expression (31). Also, the 
absence of a source of steroidal precursors for estrogen 
biosynthesis in this in vitro system prevented significant 
estrogen production (32).
Figure 5
The clearance of follitropin delta (blue circles) and follitropin alfa  
(red squares) was compared following intravenous injection in rat, in the 
presence of a saturating dose of ASF (filled symbols), or the absence of 
co-injected ASF (open symbols). Serum taken at the indicated time points 
was analyzed for rFSH concentration. A Student’s t-test compared results 
in the presence or absence of ASF, with an asterisk (*) indicating a 
significant difference (P < 0.05).
Figure 6
The clearance of follitropin delta (blue circles) and follitropin alfa  
(red squares) was compared in wild-type mice (open symbols) and Asgpr 
knockout mice (filled symbols), determining rFSH concentration present 
in serum at varying time points. A Student’s t-test compared results in the 
presence or absence of ASF, with an asterisk (*) indicating a significant 
difference (P < 0.05).
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The differences in follitropin delta and follitropin 
alfa responses in rats and in women may be due in part 
to differences in pharmacokinetics, including clearance. 
A potential mechanism of rFSH clearance from serum is 
by hepatic asialoglycoprotein receptor (ASGPR), which 
mediates the rapid clearance from serum of glycoproteins 
containing terminal galactose, GalNac or alpha2,6 sialic 
acid, and GalNac with 2.6 sialic acid, the latter having a 
high affinity for the rat ASGPR (33, 34).
Inhibition of ASGPR-dependent clearance in 
rats by co-injection of a saturating dose of ASF (35) 
reduced clearance of follitropin delta from serum but 
did not affect follitropin alfa clearance. Similarly, the 
clearance of follitropin delta was reduced in Asgpr 
knockout mice compared to wild-type mice, further 
supporting the role of the hepatic ASGPR in clearance 
of follitropin delta but not follitropin alfa from serum. 
This difference in rFSH clearance from serum by the 
liver is likely to result in differing metabolic fates for 
the two rFSH proteins.
Other factors might also play a role in the 
distinct pharmacokinetics of follitropin delta. Human 
expression of hepatic ASGPR is lower than in mouse or 
rodent, suggesting less dependence on this clearance 
mechanism in humans (36). Renal clearance also plays 
a role in FSH pharmacokinetics, and the greater sialic 
acid content of follitropin delta compared to follitropin 
alfa, with increased charge and size, is likely to result 
in lower renal clearance (37, 38) as well as impacting 
hepatic clearance.
The distinct properties of follitropin delta have 
important implications for its pharmacology and clinical 
use. The Steelman–Pohley assay for the determination of 
FSH bioactivity utilizes a recombinant reference standard 
(1st IS FSH, recombinant 92/642) expressed in CHO cells. 
As a result, bioactivity in the Steelman–Pohley assay 
compared to the reference standard does not directly 
predict the pharmacodynamic response of follitropin 
delta in humans, as was observed. Dosing follitropin delta 
according to mass rather than bioactivity measured in rat 
is important as a result. This principle is being pursued in 
follitropin delta clinical development, with individualized 
dosing by mass optimized for each patient based on their 
AMH level and weight (11, 12). The differences between 
the pharmacology of follitropin delta and follitropin alfa 
also suggest that one should not be directly substituted for 
the other in one clinical procedure. Future innovation 
in the treatment of infertility should continue to consider 
the impact of the unique properties of rFSH proteins on 
their therapeutic use.
Declaration of interest
Glenn Croston was paid as a consultant by Ferring Pharmaceuticals. 
Daniel Plaksin is an employee of BTG Israel, a subsidiary of Ferring 
Pharmaceuticals. Claus Yding Andersen, Janni V Jeppesen and Kirsten 
T Macklon received funding from Ferring Pharmaceuticals. Wolfgang 
Koechling is an employee of Ferring Pharmaceuticals A/S.
Funding
This research was funded by Ferring Pharmaceuticals and its subsidiaries.
References
 1 Howles CM. Role of LH and FSH in ovarian function. Molecular 
and Cellular Endocrinology 2000 161 25–30. (doi:10.1016/S0303-
7207(99)00219-1)
 2 Macklon NS, Stouffer RL, Giudice LC & Fauser BC. The science behind 
25 years of ovarian stimulation for in vitro fertilization. Endocrine 
Reviews 2006 27 170–207. (doi:10.1210/er.2005-0015)
 3 Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L & 
Devroey P. GnRH antagonists in ovarian stimulation for IVF. Human 
Reproduction Update 2006 12 333–340. (doi:10.1093/humupd/dml001)
 4 Howles CM. Genetic engineering of human FSH (Gonal-F). Human 
Reproduction Update 1996 2 172–191. (doi:10.1093/humupd/2.2.172)
 5 Goa KL & Wagstaff AJ. Follitropin alpha in infertility: a review. 
BioDrugs 1998 9 235–260. (doi:10.2165/00063030-199809030-00006)
 6 Out HJ, Mannaerts BM, Driessen SG & Coelingh Bennink HJ. 
Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted 
reproduction: more oocytes, more pregnancies. Results from five 
comparative studies. Human Reproduction Update 1996 2 162–171. 
(doi:10.1093/humupd/2.2.162)
 7 Wang H, Chen X, Zhang X, Zhang W, Li Y, Yin H, Shao H & Chen 
G. Comparative assessment of glycosylation of a recombinant 
human FSH and a highly purified FSH extracted from human urine. 
Journal of Proteome Research 2016 15 923–932. (doi:10.1021/acs.
jproteome.5b00921)
 8 Hård K, Mekking A, Damm JB, Kamerling JP, de Boer W, Wijnands 
RA & Vliegenthart JF. Isolation and structure determination of the 
intact sialylated N-linked carbohydrate chains of recombinant human 
follitropin expressed in Chinese hamster ovary cells. European Journal 
of Biochemistry 1990 193 263–271. (doi:10.1111/j.1432-1033.1990.
tb19332.x)
 9 Olijve W, de Boer W, Mulders JW & van Wezenbeek PM. Molecular 
biology and biochemistry of human recombinant follicle stimulating 
hormone (Puregon). Molecular Human Reproduction 1996 2 371–382. 
(doi:10.1093/molehr/2.5.371)
 10 World Intellectual Property Organization (WO 2013/020996 A1) 
Composition for controlled ovarian stimulation.
 11 Arce JC, Andersen AN, Fernández-Sánchez M, Visnova H, Bosch E, 
García-Velasco JA, Barri P, de Sutter P, Klein BM & Fauser BC. Ovarian 
response to recombinant human follicle-stimulating hormone: a 
randomized, antimüllerian hormone-stratified, dose-response trial 
in women undergoing in vitro fertilization/intracytoplasmic sperm 
injection. Fertility and Sterility 2014 102 1633–1640. (doi:10.1016/j.
fertnstert.2014.08.013)
 12 Bosch E, Nyboe Andersen A, Barri P, García-Velasco JA, de Sutter P, 
Fernández-Sánchez M, Visnova H, Klein BM, Mannaerts B & Arce 
JC. Follicular and endocrine dose responses according to anti-
Müllerian hormone levels in IVF patients treated with a novel 
human recombinant FSH (FE 999049). Clinical Endocrinology 2015 83 
902–912. (doi:10.1111/cen.12864)
 13 Olsson H, Sandstrom R & Grundemar L. Different pharmacokinetic 
and pharmacodynamic properties of recombinant follicle-stimulating 
hormone (rFSH) derived from a human cell line compared with rFSH 
This work is licensed under a Creative Commons 
Attribution 4.0 International License.DOI: 10.1530/EC-17-0067
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
Research W Koechling, D Plaksin et al. Comparative pharmacology of 
follitropin delta
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:305305–305
from a non-human cell line. Journal of Clinical Pharmacology 2014 54 
1299–1307. (doi:10.1002/jcph.328)
 14 World Intellectual Property Organization (WO 2009/127826 A1) 
Recombinant FSH including alpha 2,3 and alpha 2,6 sialylation.
 15 Ulloa-Aguirre A, Damián-Matsumura P, Jiménez M, Zambrano E & 
Díaz-Sánchez V. Biological characterization of the naturally occurring 
analogues of intrapituitary human follicle-stimulating hormone. 
Human Reproduction 1992 7 23–30. (doi:10.1093/oxfordjournals.
humrep.a137550)
 16 de Leeuw R, Mulders J, Voortman G, Rombout F, Damm J & 
Kloosterboer L. Structure-function relationship of recombinant follicle 
stimulating hormone (Puregon). Molecular Human Reproduction 1996 2 
361–369. (doi:10.1093/molehr/2.5.361)
 17 Timossi CM, Barrios-de-Tomasi J, González-Suárez R, Arranz MC, 
Padmanabhan V, Conn PM & Ulloa-Aguirre A. Differential effects of 
the charge variants of human follicle-stimulating hormone. Journal of 
Endocrinology 2000 165 193–205. (doi:10.1677/joe.0.1650193)
 18 Creus S, Chaia Z, Pellizzari EH, Cigorraga SB, Ulloa-Aguirre A 
& Campo S. Human FSH isoforms: carbohydrate complexity as 
determinant of in vitro bioactivity. Molecular and Cellular Endocrinology 
2001 174 41–49. (doi:10.1016/S0303-7207(00)00453-6)
 19 Andersen CY & Ezcurra D. What is the clinical relevance of follicle-
stimulating hormone isoforms in fertility treatment? Reproductive 
Biology Insights 2011 4 1–10. (doi:10.4137/RBI.S7362)
 20 Cheng Y & Prusoff WH. Relationship between the inhibition constant 
(Ki) and the concentration of inhibitor which causes 50 per cent 
inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 
1973 22 3099–3108. (doi:10.1016/0006-2952(73)90196-2)
 21 Ryding J, Hjertberg E & Rasmussen BB. Comparison of two direct 
neutralizing assay formats using recombinant follicle-stimulating 
hormone as agonist. Journal of Immunological Methods 2013 400–401 
87–96. (doi:10.1016/j.jim.2013.10.008)
 22 Borgbo T, Sommer Kristensen L, Lindgren I, Yding Andersen C 
& Hansen LL. Genotyping common FSHR polymorphisms based 
on competitive amplification of differentially melting amplicons 
(CADMA). Journal of Assisted Reproduction and Genetics 2014 31 
1427–1426. (doi:10.1007/s10815-014-0329-6)
 23 Schmittgen TD & Livak KJ. Analyzing real-time PCR data by the 
comparative CT method. Nature Protocols 2008 3 1101–1108. 
(doi:10.1038/nprot.2008.73)
 24 Steelman SL & Pohley FM. Assay of the follicle stimulating hormone 
based on the augmentation with human chorionic gonadotrophin. 
Endocrinology 1953 53 604–614. (doi:10.1210/endo-53-6-604)
 25 Ishibashi S, Hammer RE & Herz J. Asialoglycoprotein receptor 
deficiency in mice lacking the minor receptor subunit. Journal of 
Biological Chemistry 1994 269 27803–27806.
 26 Sasson R, Rimon E, Dantes A, Cohen T, Shinder V, Land-Bracha 
A & Amsterdam A. Gonadotrophin-induced gene regulation in 
human granulosa cells obtained from IVF patients. Modulation 
of steroidogenic genes, cytoskeletal genes and genes coding for 
apoptotic signaling and protein kinases. Molecular Human Reproduction 
2004 10 299–311. (doi:10.1093/molehr/gah041)
 27 Rimon E, Sasson R, Dantes A, Land-Bracha A & Amsterdam A. 
Gonadotropin-induced gene regulation in human granulosa cells 
obtained from IVF patients: modulation of genes coding for growth 
factors and their receptors and genes involved in cancer and other 
diseases. International Journal of Oncology 2004 24 1325–1338. 
(doi:10.3892/ijo.24.5.1325)
 28 Lindeberg M, Carlström K, Ritvos O & Hovatta O. Gonadotrophin 
stimulation of non-luteinized granulosa cells increases steroid 
production and the expression of enzymes involved in estrogen 
and progesterone synthesis. Human Reproduction 2007 22 401–406. 
(doi:10.1093/humrep/del408)
 29 Ophir L, Yung Y, Maman E, Rubinstein N, Yerushalmi GM, Haas J, 
Barzilay E & Hourvitz A. Establishment and validation of a model 
for non-luteinized human mural granulosa cell culture. Molecular 
and Cellular Endocrinology 2014 384 165–174. (doi:10.1016/j.
mce.2014.01.018)
 30 Loreti N, Ambao V, Andreone L, Trigo R, Bussmann U & Campo 
S. Effect of sialylation and complexity of FSH oligosaccharides 
on inhibin production by granulosa cells. Reproduction 2013 145 
127–135. (doi:10.1530/REP-12-0228)
 31 Andersen CY & Byskov AG. Estradiol and regulation of anti-Mullerian 
hormone, inhibin-A and inhibin-B secretion: analysis of small antral 
and preovulatory human follicles’ fluid. Journal of Clinical Endocrinology 
and Metabolism 2006 91 4064–4069. (doi:10.1210/jc.2006-1066)
 32 Erickson GF, Magofflin DA, Dyer CA & Hofeditz C. The ovarian 
androgen producing cells: a review of structure/function 
relationships. Endocrine Reviews 1985 6 371–399. (doi:10.1210/edrv-6-
3-371)
 33 Park EI, Manzella SM & Baenziger JU. Rapid clearance of sialylated 
glycoproteins by the asialoglycoprotein receptor. Journal of Biological 
Chemistry 2003 278 4597–4602. (doi:10.1074/jbc.M210612200)
 34 Steirer LM, Park EI, Townsend RR & Baenziger JU. The 
asialoglycoprotein receptor regulates levels of plasma 
glycoproteins terminating with sialic acid alpha2,6-galactose. 
Journal of Biological Chemistry 2009 284 3777–3783. (doi:10.1074/
jbc.M808689200)
 35 Rotundo RF, Rebres RA, Mckeown-Longo PJ, Blumenstock FA & Saba 
TM. Circulating cellular fibronectin may be a natural ligand for the 
hepatic asialoglycoprotein receptor: possible pathway for fibronectin 
deposition and turnover in the rat liver. Hepatology 1998 28 475–485. 
(doi:10.1002/hep.510280227)
 36 Poulin P. A single-species approach considering additional 
physiological information for prediction of hepatic clearance of 
glycoprotein derivate therapeutics. Clinical Pharmacokinetics 2011 50 
665–674. (doi:10.2165/11592610-000000000-00000)
 37 Emmanouel DS, Stavropoulos T & Katz AI. Role of the kidney in 
metabolism of gonadotropins in rats. American Journal of Physiology 
1984 247 E786–E792.
 38 Perlman S, van den Hazel B, Christiansen J, Gram-Nielsen S, Jeppesen 
CB, Andersen KV, Halkier T, Okkels S & Schambye HT. Glycosylation 
of an N-terminal extension prolongs the half-life and increases the 
in vivo activity of follicle stimulating hormone. Journal of Clinical 
Endocrinology and Metabolism 2003 88 3227–3235. (doi:10.1210/
jc.2002-021201)
 39 Nyboe Andersen A, Nelson SM, Fauser BCJ, Garcia-Velasco JA, 
Klein BM, Arce JC & ESTHER-1 Study Group. Individualized 
versus conventional ovarian stimulation for in vitro fertilization: 
a multicenter, randomized, controlled, assessor-blinded, phase 
3 noninferiority trial. Fertility and Sterility 2017 107 387–396. 
(doi:10.1016/j.fertnstert.2016.10.033)
Received in final form 25 April 2017
Accepted 27 April 2017
Accepted Preprint published online 27 April 2017
